T Costacou1, R W Evans2, T J Orchard2. 1. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA. costacout@edc.pitt.edu. 2. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
AIMS: We aimed to assess whether the association of the haptoglobin 2 allele with coronary artery disease is modified by glycaemic control in a prospective cohort study of individuals with childhood-onset Type 1 diabetes. METHODS: Coronary artery disease events (death from coronary artery disease, confirmed myocardial infarction, stenosis ≥50%, revascularization) were assessed between 1986 and 2013 among 480 individuals with Type 1 diabetes (baseline age 28 years; diabetes duration 19 years). Better glycaemic control was defined as an updated mean HbA1c during follow-up of <8% (64 mmol/mol). RESULTS: In crude models, the incidence of coronary artery disease increased with the number of haptoglobin 2 alleles (hazard ratio 1.34, 95% CI 1.05-1.71). This association was more pronounced in those with better than in those with worse glycaemic control (P interaction = 0.05) and remained essentially unaltered after multivariable adjustments (hazard ratio 2.65, 95% CI 1.30-5.41 in those with better glycaemic control and hazard ratio 1.20, 95% CI 0.93-1.56 in those with worse glycaemic control). CONCLUSIONS: These results suggest that, although better control may reduce the incidence of coronary artery disease in Type 1 diabetes, a residual risk related to the haptoglobin 2 allele remains.
AIMS: We aimed to assess whether the association of the haptoglobin 2 allele with coronary artery disease is modified by glycaemic control in a prospective cohort study of individuals with childhood-onset Type 1 diabetes. METHODS:Coronary artery disease events (death from coronary artery disease, confirmed myocardial infarction, stenosis ≥50%, revascularization) were assessed between 1986 and 2013 among 480 individuals with Type 1 diabetes (baseline age 28 years; diabetes duration 19 years). Better glycaemic control was defined as an updated mean HbA1c during follow-up of <8% (64 mmol/mol). RESULTS: In crude models, the incidence of coronary artery disease increased with the number of haptoglobin 2 alleles (hazard ratio 1.34, 95% CI 1.05-1.71). This association was more pronounced in those with better than in those with worse glycaemic control (P interaction = 0.05) and remained essentially unaltered after multivariable adjustments (hazard ratio 2.65, 95% CI 1.30-5.41 in those with better glycaemic control and hazard ratio 1.20, 95% CI 0.93-1.56 in those with worse glycaemic control). CONCLUSIONS: These results suggest that, although better control may reduce the incidence of coronary artery disease in Type 1 diabetes, a residual risk related to the haptoglobin 2 allele remains.
Authors: Tina Costacou; Andrew P Levy; Rachel G Miller; Janet Snell-Bergeon; Rabea Asleh; Dan Farbstein; Catherine E Fickley; Georgia Pambianco; Rona de la Vega; Rhobert W Evans; Trevor J Orchard Journal: Acta Diabetol Date: 2015-05-24 Impact factor: 4.280
Authors: Andrew P Levy; Irit Hochberg; Kathleen Jablonski; Helaine E Resnick; Elisa T Lee; Lyle Best; Barbara V Howard Journal: J Am Coll Cardiol Date: 2002-12-04 Impact factor: 24.094
Authors: Mahmoud Suleiman; Doron Aronson; Rabea Asleh; Michael R Kapeliovich; Ariel Roguin; Simcha R Meisel; Michael Shochat; Abeer Sulieman; Shimon A Reisner; Walter Markiewicz; Haim Hammerman; Rachel Lotan; Nina S Levy; Andrew P Levy Journal: Diabetes Date: 2005-09 Impact factor: 9.461
Authors: Leah E Cahill; Andrew P Levy; Stephanie E Chiuve; Majken K Jensen; Hong Wang; Nawar M Shara; Shany Blum; Barbara V Howard; Jennifer K Pai; Kenneth J Mukamal; Kathryn M Rexrode; Eric B Rimm Journal: J Am Coll Cardiol Date: 2013-01-09 Impact factor: 24.094
Authors: Ariel Roguin; Werner Koch; Adnan Kastrati; Doron Aronson; Albert Schomig; Andrew P Levy Journal: Diabetes Care Date: 2003-09 Impact factor: 19.112
Authors: Jeremy N Adams; Amanda J Cox; Barry I Freedman; Carl D Langefeld; J Jeffrey Carr; Donald W Bowden Journal: Cardiovasc Diabetol Date: 2013-02-11 Impact factor: 9.951